RNS Number : 5008V
Acambis PLC
29 May 2008
Additional listing
29 May 2008
Application has been made to The UK Listing Authority and the London Stock Exchange for
block listings totalling 1,000,000 Ordinary
shares of 10p each to trade on the London Stock Exchange and to be admitted to the Official
List. The shares shall rank equally with the
existing issued shares of the Company.
The shares will be issued under the following share schemes:
* Acambis Share Incentive Plan
* Acambis 2006 Approved Share Option Plan
* Acambis 2006 Unapproved Share Option Plan and
* Acambis 2006 Deferred Bonus Plan.
- end -
Enquiries:
Acambis' Finance Department on +44 (0) 1223 275 300
About Acambis
Acambis is a leading vaccine company developing novel vaccines that address significant
unmet medical needs or substantially improve
standards of care. ChimeriVax*-JE, Acambis' most advanced product in its development-stage
pipeline, has to date shown an excellent safety
and efficacy profile following pivotal Phase 3 trials. It is currently undergoing paediatric
trials in the endemic region and is partnered
with Sanofi Pasteur. Acambis' proprietary ChimeriVax* technology, developed in association
with St Louis University, has also been used to
develop ChimeriVax*-West Nile, which is undergoing Phase 2 clinical testing, making it the
most advanced investigational vaccine against the
West Nile virus. Acambis has established a global collaboration with Sanofi Pasteur for
further development and commercialisation of the
vaccine. ChimeriVax* has also been applied to development of Sanofi Pasteur's tetravalent
dengue vaccine, which has successfully
demonstrated proof-of-concept in a Phase 2 trial by generating 100% seroconversion to all four
dengue virus serotypes.
Acambis' ACAM-CDIFF* is the only vaccine in development against Clostridium difficile
bacteria, a leading cause of hospital-acquired
infections. C. difficile is estimated to cause at least 360,000 cases of C.difficile-associated disease in the US alone, and annual costs
to US and European healthcare systems are estimated to be in excess of $7bn a year. Acambis'
influenza programme aims to develop a universal
vaccine against influenza, for which a universal 'A' strain vaccine, ACAM-FLU-A*, was recently
tested in a Phase 1 trial and pre-clinical
challenge study. Acambis is currently undertaking pre-clinical testing of a vaccine candidate,
dl5-29, against genital herpes.
Acambis is recognised internationally as the leading producer of smallpox vaccines for
emergency-use stockpiles held by the US
Government and several other governments around the world. Acambis developed its ACAM2000*
smallpox vaccine under contracts with the US
Government.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the
London Stock Exchange (ACM). More information
is available at www.acambis.com.
"Safe Harbour" statement
Statements contained within this news release may contain forward-looking comments, which
involve risks and uncertainties that may cause
actual results to vary from those contained in the forward-looking statements. In some cases,
you can identify such forward-looking
statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans',
'anticipates', 'believes', 'estimates',
'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this
news release are subject to the satisfactory
progress of research which is, by its very nature, unpredictable. Forward projections reflect
management's best estimates based on
information available at the time of issue.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISEAESNAENPEFE
|